




**SUPPLEMENTARY FIGURE 29.** Group A: *Malondialdehyde* (MDA) levels at the control group.




**SUPPLEMENTARY FIGURE 30.** Group B: *Malondialdehyde* (MDA) levels at the Study group which Lazaroid was given at 30 minutes of acutemyocardial ischemia.



**SUPPLEMENTARY FIGURE 31.** Group C: *Malondialdehyde* (MDA) levels at the Study group which Lazaroid was given before acute myocardial ischemia.




**SUPPLEMENTARY FIGURE 32.** Group D: *Malondialdehyde* (MDA) levels at the Study group which Sildenafil was given at 30 minutes of acute myocardial ischemia.



**SUPPLEMENTARY FIGURE 33.** Group E: *Malondialdehyde* (MDA) levels at the Study group which Sildenafil was given before myocardial ischemia.



**SUPPLEMENTARY FIGURE 34.** Group F: *Malondialdehyde* (MDA) levels at the Studygroup which Combination sildenafil and lazaroïd was given at 30 minutes of acutemyocardial ischemia.



**SUPPLEMENTARY FIGURE 35.** Group G: *Malondialdehyde* (MDA) levels at the Study group which Combination sildenafil and lazardoid was given before myocardialischemia.